Clinical Trial Results:
A 52 week, randomised, double blind, multinational, multicentre, 4-arm parallel group trial to assess the efficacy and safety of 3 doses of CHF 6532 (10, 25 or 50 mg BID) compared to placebo on top of standard of care in subjects with uncontrolled severe eosinophilic asthma.
Summary
|
|
EudraCT number |
2018-003548-22 |
Trial protocol |
FR CZ HU DE BG GR PL IT |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
29 Sep 2021
|
First version publication date |
29 Sep 2021
|
Other versions |
|
Summary report(s) |
PERSEA STUDY CSR SYNOPSIS |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.